ST. Croix Regional Medical Center
ST. Croix Regional Medical Center was paid $7.03M by Medicaid between Jan 2018 and Dec 2024, across 189 billing codes. Its largest line is 99284, emergency room visit (serious) — 13% of everything it billed.
33Billing provider infoST. CROIX REGIONAL MEDICAL CENTER
SAINT CROIX FALLS, WI 54024
SAINT CROIX FALLS, WI 54024
33aNPI1043240922assigned 07/04/2006
33bProvider typeOccupational Therapy Assistant
28Total paid$7.03M
24GClaims259,715
24DCodes billed189
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 46,217 | $900K | |
| 2019 | 33,851 | $861K | |
| 2020 | 26,047 | $952K | |
| 2021 | 39,984 | $1.10M | |
| 2022 | 36,335 | $1.07M | |
| 2023 | 41,409 | $1.15M | |
| 2024incomplete | 35,872 | $1.00M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 7,776 | 6,163 | $889K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 6,088 | 4,896 | $871K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 8.0% | 19,587 | 16,012 | $562K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.8% | 4,292 | 3,307 | $547K |
| 96361 | Intravenous infusion, hydration; each additional hour | 7.4% | 1,680 | 1,151 | $522K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 6.7% | 13,011 | 9,354 | $470K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.6% | 3,185 | 2,659 | $257K |
| 90837 | Psychotherapy session, about an hourPsychotherapy, 53 minutes with patient | 3.1% | 2,489 | 1,086 | $216K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.0% | 1,897 | 1,554 | $213K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 2.4% | 8,399 | 3,405 | $171K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.4% | 796 | 628 | $170K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.3% | 4,498 | 3,821 | $162K |
177 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.9% | 1,049 | $137K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.5% | 1,057 | $106K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.5% | 3,758 | $105K |
| 80053 | Comprehensive metabolic panel | 1.5% | 5,859 | $105K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.1% | 5,171 | $79K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.1% | 5,604 | $79K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 1.0% | 209 | $73K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 226 | $57K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,819 | $53K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 11,866 | $52K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,024 | $52K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 1,364 | $51K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,904 | $45K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,462 | $43K |
| 73630 | <1% | 1,802 | $43K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,462 | $42K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,377 | $37K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,755 | $37K |
| 97162 | <1% | 999 | $32K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,379 | $29K |
| 80061 | Lipid panel | <1% | 2,741 | $27K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 157 | $27K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 5,971 | $27K |
| 95886 | <1% | 609 | $25K | |
| 95913 | <1% | 62 | $24K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,098 | $22K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 455 | $22K |
| 36415 | Collection of venous blood by venipuncture | <1% | 13,858 | $21K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 85 | $20K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 37 | $20K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,749 | $19K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,688 | $17K |
| 81025 | <1% | 2,257 | $17K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,507 | $17K |
| 80306 | <1% | 1,117 | $16K | |
| 87081 | <1% | 1,939 | $16K | |
| G2025 | Payment for a telehealth distant site service furnished by a rural health clinic (rhc) or federally qualified health center (fqhc) only | <1% | 852 | $15K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,045 | $14K |
| 81001 | <1% | 5,141 | $13K | |
| 73562 | <1% | 591 | $13K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 511 | $13K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,945 | $12K |
| 84484 | <1% | 1,810 | $11K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 739 | $11K |
| 85610 | <1% | 4,125 | $11K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,794 | $9K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 333 | $9K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 42 | $8K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,033 | $8K |
| 86803 | <1% | 806 | $8K | |
| 86140 | <1% | 2,429 | $8K | |
| 82565 | <1% | 1,791 | $8K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 270 | $7K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,999 | $7K |
| 86703 | <1% | 608 | $6K | |
| 97035 | <1% | 708 | $6K | |
| 99441 | <1% | 194 | $6K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 75 | $6K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 46 | $6K |
| 90686 | <1% | 770 | $6K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 230 | $5K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 14 | $5K |
| 84460 | <1% | 1,637 | $5K | |
| 73030 | <1% | 242 | $5K | |
| 83690 | <1% | 1,045 | $5K | |
| 87186 | <1% | 815 | $5K | |
| 36416 | <1% | 2,952 | $4K | |
| 72100 | <1% | 216 | $4K | |
| 86850 | <1% | 1,024 | $4K | |
| 87210 | <1% | 685 | $4K | |
| 86780 | <1% | 470 | $4K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 189 | $4K |
| 82607 | <1% | 393 | $4K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 75 | $4K |
| 93976 | <1% | 36 | $4K | |
| 73610 | <1% | 242 | $4K | |
| 76830 | Ultrasound, transvaginal | <1% | 45 | $4K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,215 | $4K |
| 96367 | <1% | 17 | $3K | |
| V5266 | Battery for use in hearing device | <1% | 335 | $3K |
| 86618 | <1% | 187 | $3K | |
| 84450 | <1% | 956 | $3K | |
| 83735 | <1% | 1,008 | $3K | |
| 83605 | <1% | 505 | $3K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 63 | $3K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 262 | $3K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 280 | $2K |
| 73130 | <1% | 77 | $2K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 45 | $2K |
| 82248 | <1% | 812 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 35 | $2K |
| 83655 | <1% | 195 | $2K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 82 | $2K |
| 20553 | <1% | 35 | $2K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,834 | $2K |
| 82948 | <1% | 1,087 | $2K | |
| 87077 | <1% | 355 | $2K | |
| 82728 | <1% | 184 | $2K | |
| 85652 | <1% | 1,168 | $2K | |
| 85027 | <1% | 483 | $2K | |
| 80050 | General health panel | <1% | 137 | $2K |
| 76801 | <1% | 18 | $1K | |
| 83880 | <1% | 115 | $1K | |
| 82077 | <1% | 156 | $1K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 104 | $1K |
| L4361 | Walking boot, pneumatic and/or vacuum, with or without joints, with or without interface material, prefabricated, off-the-shelf | <1% | 16 | $1K |
| 85018 | <1% | 565 | $1K | |
| 0011A | <1% | 49 | $1K | |
| 71250 | <1% | 40 | $1K | |
| 0012A | <1% | 44 | $1K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 15 | $1K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 12 | $1K |
| 87340 | <1% | 141 | $986.48 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 48 | $964.75 |
| 73110 | <1% | 31 | $941.12 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 152 | $900.06 |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 14 | $861.06 |
| J3490 | Unclassified drugs | <1% | 244 | $807.28 |
| 72040 | <1% | 12 | $784.40 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 30 | $768.57 |
| 86900 | <1% | 358 | $743.78 | |
| 86901 | <1% | 358 | $716.69 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 19 | $709.75 |
| 84702 | <1% | 24 | $679.06 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,047 | $581.49 |
| 83550 | <1% | 87 | $568.89 | |
| 83540 | <1% | 104 | $510.26 | |
| 84439 | <1% | 63 | $476.72 | |
| 90670 | <1% | 151 | $443.54 | |
| 87040 | <1% | 112 | $402.88 | |
| 82570 | <1% | 121 | $401.25 | |
| 97163 | <1% | 29 | $382.36 | |
| 92567 | <1% | 25 | $371.81 | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,876 | $370.96 |
| 90723 | <1% | 113 | $347.55 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,533 | $297.69 |
| 80076 | <1% | 44 | $293.64 | |
| 84156 | <1% | 117 | $291.83 | |
| 99442 | <1% | 17 | $275.52 | |
| 90685 | <1% | 87 | $268.11 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 13 | $248.80 |
| 92593 | <1% | 16 | $245.67 | |
| 82043 | <1% | 40 | $173.13 | |
| 64405 | <1% | 25 | $157.50 | |
| 90647 | <1% | 54 | $145.64 | |
| 84145 | <1% | 32 | $142.85 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,289 | $119.07 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,115 | $107.96 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,197 | $97.41 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,871 | $96.84 |
| 85379 | <1% | 15 | $94.68 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,823 | $93.49 |
| 93793 | <1% | 206 | $85.25 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,942 | $85.08 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 332 | $81.50 |
| 98960 | <1% | 15 | $80.77 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,496 | $61.05 |
| 99000 | <1% | 25 | $55.52 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,606 | $33.17 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,643 | $29.03 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 334 | $28.01 |
| 96376 | <1% | 36 | $18.55 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 82 | $12.84 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 246 | $11.01 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 649 | $4.16 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 87 | $0.00 |
| A9270 | Non-covered item or service | 0% | 496 | $0.00 |
| 36591 | 0% | 16 | $0.00 | |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 22 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 15 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 97 | $0.00 |
| 91301 | 0% | 128 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 50 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 61 | $0.00 |
| 90662 | 0% | 19 | $0.00 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 17 | $0.00 |
| 99152 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialYOUSO, MIKE (CFO)
| Provider | Location | Paid |
|---|---|---|
| ST. Croix Regional Medical Center | Saint Croix Falls, WI | $958K |
| ST. Croix Regional Medical Center | Webster, WI | $387K |
| ST. Croix Regional Medical Center | Balsam Lake, WI | $311K |
| ST. Croix Regional Medical Center | Frederic, WI | $267K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.